Latest Rhinitis Stories
Circassia, a specialty biopharmaceutical company, has started a further Phase II clinical study of its ToleroMune technology in the field of cat allergy. The trial builds on positive results achieved in an earlier Phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization. In the previous Phase II clinical trial, patients experienced substantially reduced reactions to cat allergens after a single administration of ToleroMune...
OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization. In the previous phase II clinical trial,...
Breathe Again(TM), Europe's best selling hypertonic saline nasal spray, is now available in the United States. Clinically tested in France, Breathe Again (www.breatheagain.us) is 100% natural, combining the benefits of pure seawater and the drying effect of a hypertonic solution. Harvested from Europe's purest tidal seawater off the coast of Saint Malo, France, the superior and unique nasal spray can be used for allergy prevention, nasal congestion, sinus problems and nasal hygiene. With...
Sanofi-Aventis has announced that the FDA has approved Nasacort AQ nasal spray for children aged two to five years old for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis. The FDA based its approval on the results of a multicenter, randomized, double-blind, placebo-controlled study demonstrating that Nasacort AQ can be used safely and effectively to treat nasal symptoms of year-round allergies in children between two and five years. This is said to...
Nasacort, a nasal steroid used in allergic rhinitis, has been approved for the treatment of children aged two to five years old. Although the breadth of its label is now similar to that of some of its competitors, Datamonitor does not expect that the expanded approval will have a significant impact on sales. Sanofi-Aventis has announced that the FDA has approved the use of Nasacort nasal spray (triamcinolone), the company's treatment of nasal symptoms associated with seasonal and perennial...
BRIDGEWATER, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today the U.S. Food and Drug Administration (FDA) has approved Nasacort AQ Nasal Spray (triamcinolone acetonide) for children aged 2-5 years old for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis. The FDA based its approval on the results of a multicenter, randomized, double-blind, placebo-controlled study demonstrating that Nasacort AQ can be used safely and effectively...
A COMMON painkiller may be one of the key driving forces behind the worldwide epidemic of childhood asthma, reveals a major study today. Researchers who analysed data on more than 200,000 children found strong links between paracetamol use and both the development of asthma and the symptoms' appearance. Taking paracetamol once a month more than tripled the chances of six and seven-year-olds suffering wheezing attacks. The drug was also associated with an increased risk of...
OXFORD, England, September 10 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune(R), in the field of cat allergy. The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and importantly was well tolerated by all patients. Circassia conducted...
An allergy educational group has named Greensboro, N.C., as the most challenging place to live for people with seasonal allergies. Greenville, S.C., Little Rock, Ark., Raleigh-Durham, N.C., and Jackson, Miss., rounded out the top five on the list compiled by the Asthma and Allergy Foundation of America. The group said fall brings new allergy triggers that are not prevalent in the spring, such as ragweed. "During the fall when outdoor allergy triggers peak, people may continue to suffer from...
Orexo, a Swedish pharmaceutical company, has initiated a Phase II program for the product OX914, a new candidate for the treatment of inflammatory airway diseases including asthma, chronic obstructive pulmonary disease and rhinitis. The patients will be treated with OX914 in a disease model for inflammatory airway disease. Approximately 36 patients with seasonal allergic rhinitis will be given placebo or OX914 in doses of 15 or 50mg for two weeks in a double-blind three-way cross-over study....
